Add this topic to your myFT Digest for news straight to your inbox
Report from Nuffield Trust health think-tank highlights impact of leaving EU on medicine supply chains
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
WuXi AppTec and WuXi Biologics under threat from proposed national security legislation
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
GQG Partners argues that pharma group has performed strongly under long-serving chief
The generics sector is not getting the boost it needs from government
A company launched in 1963 confronts challenge of adapting to the rise of anti-obesity injections
Sector’s biggest company says it is talking to exchanges in London and Frankfurt
US healthcare company is putting cash to work from spinning off its consumer health arm
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
WHO member states are struggling to agree the terms of the first global treaty to deal with the threat of another Covid-19
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Europe’s regulations have become ‘too burdensome’ and could hinder innovation, argues Michael Lohan
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it
Shareholder advisory groups say potential £18.7mn payout is excessive
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Record shortages of common drugs have countries scrambling for alternatives while patients skip treatments
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Madrigal is the first to win approval for a treatment for a liver disease that affects one in 20
International Edition